Thienothiazines
Apexbio Technology LLC Brinzolamide 138890-62-7 50mg
Brinzolamide (CAS 138890-62-7) is a potent and selective inhibitor of carbonic anhydrase II (CA II) with an IC50 of 3 19 nM and a Ki of 0 13 nM in vitro By inhibiting CA II brinzolamide disrupts the reversible hydration of carbon dioxide thereby reducing aqueous humor production and lowering intraocular pressure Demonstrated to have higher affinity and inhibitory efficacy for CA II compared to CA I and CA IV brinzolamide has been shown to significantly decrease intraocular pressure in animal models Additionally it is utilized in research settings to assess cerebral blood flow reserve as CA inhibition modulates tissue CO2 levels and consequent vasodilation
Apexbio Technology LLC Brinzolamide 138890-62-7 10mM (in 1mL DMSO)
Brinzolamide (CAS 138890-62-7) is a potent and selective inhibitor of carbonic anhydrase II (CA II) with an IC50 of 3 19 nM and a Ki of 0 13 nM in vitro By inhibiting CA II brinzolamide disrupts the reversible hydration of carbon dioxide thereby reducing aqueous humor production and lowering intraocular pressure Demonstrated to have higher affinity and inhibitory efficacy for CA II compared to CA I and CA IV brinzolamide has been shown to significantly decrease intraocular pressure in animal models Additionally it is utilized in research settings to assess cerebral blood flow reserve as CA inhibition modulates tissue CO2 levels and consequent vasodilation
Medchemexpress LLC Brinzolamide | 138890-62-7 | 99.9% | 5 MG
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. This compound reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion, making it suitable for glaucoma disease research.
- Selective carbonic anhydrase II inhibitor
- Reduces intraocular pressure (IOP)
- Inhibits ciliary CA-II and decreases atrial fluid secretion
- Suitable for glaucoma disease research
Medchemexpress LLC Brinzolamide | 138890-62-7 | 99.9% | 50 MG
Brinzolamide is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. It reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion, and can be used in glaucoma disease research.
- Selective carbonic anhydrase II inhibitor
- IC50 value of 3.2 nM
- Reduces intraocular pressure (IOP) by inhibiting ciliary CA-II
- Can be used in glaucoma disease research
- Molecular weight: 383.51
- Formula: C12H21N3O5S3
- Appearance: Solid
- Color: Light yellow to yellow
Medchemexpress LLC Brinzolamide | 138890-62-7 | 99.91% | 1 ML
Brinzolamide (AL-4862) is a highly selective carbonic anhydrase II inhibitor, demonstrating an IC50 value of 3.2 nM. It functions by reducing intraocular pressure through the inhibition of ciliary CA-II, thereby decreasing atrial fluid secretion. This compound is utilized in the topical treatment of elevated intraocular pressure in individuals diagnosed with ocular hypertension or open-angle glaucoma.
- Selective carbonic anhydrase II inhibitor
- IC50 value of 3.2 nM
- Reduces intraocular pressure
- Inhibits ciliary CA-II
- Decreases atrial fluid secretion
- Used for ocular hypertension
- Used for open-angle glaucoma
Medchemexpress LLC Brinzolamide | 138890-62-7 | 99.9% | 25 MG
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor, demonstrating an IC50 value of 3.2 nM. It effectively reduces intraocular pressure by inhibiting ciliary CA-II and decreasing atrial fluid secretion. This compound is valuable for research in glaucoma disease.
- Selective carbonic anhydrase II inhibitor
- IC50 value of 3.2 nM
- Reduces intraocular pressure (IOP)
- Useful in glaucoma disease research
AdipoGen Brinzolamide
Chemical. CAS 138890-62-7. Formula C12H21N3O5S3. MW 383.51. Synthetic. Brinzolamide is a potent inhibitor of carbonic anhydrases IC50=3.2nM and 45.3nM for CAII and CAIV, respectively that lowers intraocular pressure by locally inhibiting carbonic anhydrase in the ciliary processes and suppressing aqueous humor secretion. Animal studies have found that one week of twice-daily topical ocular treatment with 2% brinzolamide significantly reduced IOP and enhanced optic nerve head blood flow.
AdipoGen Brinzolamide
Chemical. CAS 138890-62-7. Formula C12H21N3O5S3. MW 383.51. Synthetic. Brinzolamide is a potent inhibitor of carbonic anhydrases IC50=3.2nM and 45.3nM for CAII and CAIV, respectively that lowers intraocular pressure by locally inhibiting carbonic anhydrase in the ciliary processes and suppressing aqueous humor secretion. Animal studies have found that one week of twice-daily topical ocular treatment with 2% brinzolamide significantly reduced IOP and enhanced optic nerve head blood flow.
Medchemexpress LLC Brinzolamide | 138890-62-7 | 99.9% | 100 MG
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. It reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion, and can be used in glaucoma disease research.
- Selective carbonic anhydrase II inhibitor
- IC50 value of 3.2 nM
- Reduces intraocular pressure (IOP)
- Suitable for glaucoma disease research
- Molecular weight: 383.51
- Molecular formula: C12H21N3O5S3
- Appears as a solid, light yellow to yellow
Apexbio Technology LLC Lornoxicam 70374-39-9 10mM (in 1mL DMSO)
Lornoxicam (CAS 70374-39-9) is an oxicam-class nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacological effects primarily by potent inhibition of cyclooxygenase isoforms COX-1 and COX-2 with in vitro IC50 values of 5 nM and 8 nM respectively Studies in intact human cells and whole blood confirm its strong suppressive activity against both COX isoenzymes Additionally lornoxicam displays dose-dependent inhibition of nitric oxide formation (IC50 65 M) and reduction of IL-6 production in vitro Due to its robust COX inhibition and favorable pharmacokinetic profile lornoxicam is widely utilized as a research tool in studies investigating inflammation pain pathways and COX-mediated prostaglandin synthesis
Apexbio Technology LLC Lornoxicam 70374-39-9 200mg
Lornoxicam (CAS 70374-39-9) is an oxicam-class nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacological effects primarily by potent inhibition of cyclooxygenase isoforms COX-1 and COX-2 with in vitro IC50 values of 5 nM and 8 nM respectively Studies in intact human cells and whole blood confirm its strong suppressive activity against both COX isoenzymes Additionally lornoxicam displays dose-dependent inhibition of nitric oxide formation (IC50 65 M) and reduction of IL-6 production in vitro Due to its robust COX inhibition and favorable pharmacokinetic profile lornoxicam is widely utilized as a research tool in studies investigating inflammation pain pathways and COX-mediated prostaglandin synthesis